A novel vaccine against vaginal Chlamydia trachomatis

描述（由申请人提供）：预防沙眼衣原体（Ct）感染是一个关键的未满足的医疗需求。开发一种有效的疫苗不仅可以减少与这些感染相关的发病率，包括盆腔炎（PID）、不孕症、慢性盆腔疼痛和异位妊娠，还可以减少附带风险，包括艾滋病毒传播。尽管经过几十年的努力，目前还没有疫苗可用。产生有用疫苗的能力受到以下因素的限制：1)缺乏一种有效的方法来传递抗原，从而引发保护性的肱骨和细胞介导的反应；2)鉴定特定的抗原序列，以保护个人免受引起性传播疾病（STD）的Ct菌株的侵害。由EpitoGenesis， Inc.开发的专有营养免疫增强传递系统（NIDS）和Dean实验室进行的基础广泛的序列评估，以及关于Ct和HIV-1疫苗构建的令人兴奋的初步数据，提供了一个独特的机会，最终获得一种有效的疫苗，可以通过使用由该新型抗原构建物配制的新型抗原构建物来防止阴道传播Ct。安全有效的NIDS用于粘膜和全身疫苗接种。此外，粘膜和全身疫苗接种途径的结合，缺乏与人类抗原的序列同源性，以及来自EpitoGenesis和Dean实验室的有希望的初步结果，保证了一种新的疫苗设计和疫苗接种方法，有望取得成功。

DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. Despite decades of efforts, no vaccine is currently available. The ability to generate a useful vaccine has been limited by 1) the lack of an effective method to deliver antigens that will elicit protective humeral and cell-mediated responses, and 2) the identification of specific antigenic sequences that would protect individuals from the Ct strains that cause sexually transmitted diseases (STD). The proprietary nutritive immune-enhancing delivery system (NIDS) developed by EpitoGenesis, Inc. and the broad-based sequence assessment performed by the Dean lab, in addition to the exciting preliminary data on an Ct and HIV-1 vaccine constructs, provide a unique opportunity to finally obtain an efficacious vaccine that can protect against vaginal transmission of Ct through the use of the novel antigenic constructs formulated with the novel, safe and effective NIDS for mucosal and systemic vaccinations. Furthermore, combinations of mucosal and systemic vaccination routes, lack of sequence homology to human antigens, and promising preliminary results from both EpitoGenesis and the Dean lab warrant a novel vaccine design and vaccination approach that hold promise of success.